PAB.AU · Patrys Limited

-

Please sign in to comment on PAB.AU

1 Comment

Admin

4 years, 8 months ago

Patrys Limited is currently in a long term uptrend where the price is trading 93.3% above its 200 day moving average.

From a valuation standpoint, the stock is 296.1% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 1019.8.

Patrys Limited's total revenue rose by 78.1% to $215K since the same quarter in the previous year.

Its net income has dropped by 17.2% to $-2M since the same quarter in the previous year.

Finally, its free cash flow fell by 76.3% to $-778K since the same quarter in the previous year.

Based on the above factors, Patrys Limited gets an overall score of 2/5.

Sector
Exchange	AU
CurrencyCode	AUD
Industry
ISIN	AU000000PAB9

Market Cap	10M
Beta	0.7
PE Ratio	None
Target Price	0.12
Dividend Yield	None

ABOUT

Patrys Limited

Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and NETosis-driven inflammatory diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10; and PAT-DX3 for treating primary and secondary brain cancers, and metastases that are associated with NETosis, or in combination with DNA damaging agents, such as radiation and other chemotherapy drugs. The company was incorporated in 2006 and is based in Nedlands, Australia.

PAB.AU · Patrys Limited

-

Patrys Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Patrys Limited using a moving average strategy